Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02328014
Recruitment Status : Active, not recruiting
First Posted : December 31, 2014
Last Update Posted : September 19, 2019
Information provided by (Responsible Party):
Acerta Pharma BV

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020